![](https://www.neurochlore.fr/wp-content/uploads/2022/07/pexels-tara-winstead-8386440.jpg)
Although the phase III clinical trial was a failure, Neurochlore was able to retrieve data that could be promising. Indeed, we are convinced that Bumetanide works on sub-populations, defined by more specific criteria that were not considered in the selection of the initial trial. We have entered into a partnership with the company Quinten Health … Information note on the re-use of your health data